KOL Perspectives: Novel treatment options for moderate UC
Orbisresearch.com published “Novel treatment options for moderate UC Market” from its database. The report focuses on major leading industry players with information such as company profiles, product picture and specification.
(EMAILWIRE.COM, October 24, 2018 ) This KOL Insight briefing focuses on KOLs views of novel treatment options for moderate UC.
The briefing includes analysis of KOL opinion on the following topic areas -
- Current clinical management of moderate UC patients
- Awareness of novel therapies in development suitable for moderate UC
- Perception of Phase II apremilast data in moderate UC
- Expectations for treatment algorithm positioning of apremilast
- Potential for future combination therapy with apremilast
- Perception of apremilast's other labels in psoriasis (PsO) and psoriatic arthritis (PsA)
Key Players:
• Celgene
Get Sample Copy of this Report@ http://www.orbisresearch.com/contacts/request-sample/2350564
Key Highlights:
- Nearly half of all UC patients seen in the majority of KOLs’ clinical practices are considered as having moderate UC
- Most KOLs would initially treat moderate UC patients with 5-ASAs, moving to anti-TNF therapies if patients do not respond
- KOLs stated that less than 10% of moderate UC patients required surgical intervention.
Scope:
- The insight briefing is based on Sociable Pharma’s analysis of primary research with our inflammatory bowel disease key opinion leaders (KOLs)
- In total, we conducted interviews with 10 KOLs: 5 Europe-based & 5 N. America-based
- Interviews performed during March 2018
- KOL data is analyzed to produce: Charts summarizing KOL opinions
- Chart call-outs of key information & details
- KOL quotes
- Summary of KOL reporting trends
- Insight from Sociable Pharma's analysts.
Make an Inquiry before Buying@ http://www.orbisresearch.com/contacts/enquiry-before-buying/2350564
Reasons to buy:
- Combines Qualitative & semi-quantitative insight from key opinion leaders on "novel treatment options for moderate UC"
- Includes insight & recommendations from our disease-specific healthcare analysts
- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of UC
- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.
Key Points from TOC:
Executive Summary
Background
Research Panel Composition
Results & Implications
Appendix
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
The briefing includes analysis of KOL opinion on the following topic areas -
- Current clinical management of moderate UC patients
- Awareness of novel therapies in development suitable for moderate UC
- Perception of Phase II apremilast data in moderate UC
- Expectations for treatment algorithm positioning of apremilast
- Potential for future combination therapy with apremilast
- Perception of apremilast's other labels in psoriasis (PsO) and psoriatic arthritis (PsA)
Key Players:
• Celgene
Get Sample Copy of this Report@ http://www.orbisresearch.com/contacts/request-sample/2350564
Key Highlights:
- Nearly half of all UC patients seen in the majority of KOLs’ clinical practices are considered as having moderate UC
- Most KOLs would initially treat moderate UC patients with 5-ASAs, moving to anti-TNF therapies if patients do not respond
- KOLs stated that less than 10% of moderate UC patients required surgical intervention.
Scope:
- The insight briefing is based on Sociable Pharma’s analysis of primary research with our inflammatory bowel disease key opinion leaders (KOLs)
- In total, we conducted interviews with 10 KOLs: 5 Europe-based & 5 N. America-based
- Interviews performed during March 2018
- KOL data is analyzed to produce: Charts summarizing KOL opinions
- Chart call-outs of key information & details
- KOL quotes
- Summary of KOL reporting trends
- Insight from Sociable Pharma's analysts.
Make an Inquiry before Buying@ http://www.orbisresearch.com/contacts/enquiry-before-buying/2350564
Reasons to buy:
- Combines Qualitative & semi-quantitative insight from key opinion leaders on "novel treatment options for moderate UC"
- Includes insight & recommendations from our disease-specific healthcare analysts
- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of UC
- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.
Key Points from TOC:
Executive Summary
Background
Research Panel Composition
Results & Implications
Appendix
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Contact Information:
Orbis Research
Hector Costello
Tel: +1 (214) 884-6817
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Orbis Research
Hector Costello
Tel: +1 (214) 884-6817
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results